Clinical Edge Journal Scan

Migraine: Combination therapy more effective than either of manual therapies


 

Key clinical point: A combined manual therapeutic approach that included soft-tissue and articulatory manual therapy techniques was more effective in reducing migraine impact than either technique alone.

Major finding: After 4 weeks of intervention, the improvement in pain intensity was greater with combined soft-tissue and articulatory manual therapy vs only soft-tissue (P < .001) or articulatory (P = .014) manual therapy. Reduction in migraine duration was significant with combined vs soft-tissue therapy (P = .02), with improvements maintained through a 4-week follow-up. No serious side-effects were reported.

Study details: Findings are from a randomized controlled trial including 75 patients with chronic or episodic migraine who were randomly assigned to receive soft-tissue therapy, articulatory therapy, or combination of both manual therapies.

Disclosures: This study did not receive any external funding. The authors declared no conflicts of interest.

Source: Muñoz-Gómez E et al. Potential add-on effects of manual therapy techniques in migraine patients: A randomised controlled trial. J Clin Med. 2022;11(16):4686 (Aug 11). Doi: 10.3390/jcm11164686

Recommended Reading

Bariatric surgery improves symptoms, quality of life in chronic migraine
Migraine ICYMI
Diabetic retinopathy and migraine prevalence and incidence: What is the link?
Migraine ICYMI
Soy isoflavones improve migraine characteristics and CGRP levels in women with migraine
Migraine ICYMI
Possible link between dietary niacin intake and migraine prevalence
Migraine ICYMI
Meta-analysis demonstrates link between migraine and cognitive impairment
Migraine ICYMI
Erenumab, an effective option for treatment-resistant chronic migraine
Migraine ICYMI
Insights on symptoms and burden of migraine
Migraine ICYMI
CGRP antagonists effectively reduce monthly headache days in chronic migraine with medication overuse headache
Migraine ICYMI
Commentary: Better Migraine Outcomes Measures, September 2022
Migraine ICYMI
Lasmiditan effective for acute treatment of perimenstrual migraine
Migraine ICYMI